ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,321.41
      0.25%
      US Tech 100
      18,241.20
      0.25%
      Dow Jones
      39,872.99
      0.17%
      Brent Oil
      82.445
      -1.30%
      Bitcoin
      70,185.23
      -1.77%
      Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Windtree Therapeutics Inc (WINT)

      7. Windtree Therapeutics Inc (WINT) News

      WINT

      Windtree Therapeutics (WINT)

      Windtree Therapeutics Inc
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:WINT
      DateTimeSourceHeadlineSymbolCompany
      05/15/20244:59PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:WINTWindtree Therapeutics Inc
      05/09/20248:41AMEdgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:WINTWindtree Therapeutics Inc
      05/07/20248:00AMGlobeNewswire Inc.Windtree Therapeutics Regains Compliance with NasdaqNASDAQ:WINTWindtree Therapeutics Inc
      04/18/20248:00AMGlobeNewswire Inc.Windtree Therapeutics Announces Reverse Stock SplitNASDAQ:WINTWindtree Therapeutics Inc
      04/17/20248:00AMGlobeNewswire Inc.Windtree Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Key Business UpdatesNASDAQ:WINTWindtree Therapeutics Inc
      04/08/20244:48PMGlobeNewswire Inc.Windtree Acquires Early-Stage, Novel Oncology Platform and Completes $1.5 Million Convertible Note Bridge FinancingNASDAQ:WINTWindtree Therapeutics Inc
      02/16/20245:07PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:WINTWindtree Therapeutics Inc
      02/14/20245:23PMEdgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:WINTWindtree Therapeutics Inc
      02/14/20244:30PMEdgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:WINTWindtree Therapeutics Inc
      02/13/20248:15PMEdgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:WINTWindtree Therapeutics Inc
      02/12/20244:40PMEdgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:WINTWindtree Therapeutics Inc
      02/01/20245:26PMEdgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:WINTWindtree Therapeutics Inc
      02/01/20248:00AMGlobeNewswire Inc.Windtree Renews Agreement with Chang Gung University for Scientific Collaboration to Further SERCA2a ResearchNASDAQ:WINTWindtree Therapeutics Inc
      01/31/20248:40AMInvestorsHub NewsWireWindtree Therapeutics Announces Engagement of Strategic Advisor to Support Assessment of Strategic AlternativesNASDAQ:WINTWindtree Therapeutics Inc
      01/31/20248:00AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:WINTWindtree Therapeutics Inc
      01/31/20248:00AMGlobeNewswire Inc.Windtree Therapeutics Announces Engagement of Strategic Advisor to Support Assessment of Strategic AlternativesNASDAQ:WINTWindtree Therapeutics Inc
      01/25/20249:04AMInvestorsHub NewsWireWindtree Eliminates $15 Million Contingent Liability to Deerfield Management CompanyNASDAQ:WINTWindtree Therapeutics Inc
      01/25/20248:34AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:WINTWindtree Therapeutics Inc
      01/25/20248:30AMGlobeNewswire Inc.Windtree Eliminates $15 Million Contingent Liability to Deerfield Management CompanyNASDAQ:WINTWindtree Therapeutics Inc
      01/22/20244:45PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:WINTWindtree Therapeutics Inc
      01/17/20248:00AMGlobeNewswire Inc.Windtree Therapeutics Announces License Agreement with Lee’s Pharmaceuticals to Develop and Commercialize Istaroxime, Dual Mechanism SERCA2a Activators and Rostafuroxin for Greater China / Asia Pacific RegionNASDAQ:WINTWindtree Therapeutics Inc
      01/17/20247:56AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:WINTWindtree Therapeutics Inc
      01/16/20244:16PMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:WINTWindtree Therapeutics Inc
      01/02/20244:05PMGlobeNewswire Inc.Windtree Therapeutics Announces Reduction In Arrythmias In A New Study With Istaroxime And A Pure SERCA2a ActivatorNASDAQ:WINTWindtree Therapeutics Inc
      12/18/20238:00AMGlobeNewswire Inc.Windtree Therapeutics Announces the Start of Patient Dosing In Phase 2 SEISMiC Extension Study of Istaroxime in Early Cardiogenic ShockNASDAQ:WINTWindtree Therapeutics Inc
      11/16/20238:00AMGlobeNewswire Inc.Windtree Therapeutics Announces Issuance of New Pure SERCA2a Activator PatentNASDAQ:WINTWindtree Therapeutics Inc
      11/13/202311:41AMEdgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:WINTWindtree Therapeutics Inc
      11/09/20234:21PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:WINTWindtree Therapeutics Inc
      11/09/20234:15PMGlobeNewswire Inc.Windtree Therapeutics Reports Third Quarter 2023 Financial Results and Provides Key Business UpdatesNASDAQ:WINTWindtree Therapeutics Inc
      11/09/20234:11PMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:WINTWindtree Therapeutics Inc
       Showing the most relevant articles for your search:NASDAQ:WINT